Ketamine for Opioid Use Disorder: What the Emerging Research Shows

The opioid crisis has left millions of Americans cycling through treatment, relapse, and recovery — or not surviving long enough to try again. Medication-Assisted Treatment (MAT) with buprenorphine (Suboxone) or methadone saves lives and should remain the cornerstone of opioid use disorder (OUD) treatment.

But MAT doesn't work for everyone. Relapse rates remain high. The depression and psychological suffering that drive much of opioid use often go undertreated. And the craving circuitry — the deep neurological pull toward opioids — is not fully addressed by MAT alone.

This is where ketamine is beginning to show promise, carefully and honestly.

What We Know: The Evidence Base

The research on ketamine for opioid use disorder is early but increasingly compelling:

A 2022 randomized controlled trial published in the American Journal of Psychiatry found that a single IV ketamine infusion significantly reduced opioid craving in detoxified patients with heroin use disorder, with effects persisting for up to two weeks compared to a control group. The ketamine group also showed better treatment engagement and lower relapse rates at follow-up.

Studies on craving reduction: Multiple smaller studies have demonstrated that ketamine's glutamate modulation affects the reward pathways that drive craving. The mesolimbic dopamine system — the neurological substrate of addiction — is regulated by glutamate signaling. NMDA receptor antagonism appears to reduce the intensity of cue-triggered cravings, the specific moment when exposure to opioid-associated cues (people, places, emotions) triggers the compulsion to use.

Opioid-sparing effects: In patients with chronic pain who developed opioid dependence, ketamine's analgesic properties can reduce the underlying pain that drives continued opioid use — addressing the source rather than just the symptom.

Depression as a driver of opioid use: The majority of people with OUD have comorbid depression, anxiety, or PTSD. These conditions are often the psychological drivers of opioid use — using to feel something, or to not feel something. Ketamine's rapid and powerful antidepressant effect addresses this component directly, in ways that MAT does not.

What Ketamine Is NOT for OUD

Let's be clear about limitations:

Ketamine is not a replacement for buprenorphine or methadone. These medications save lives by reducing withdrawal, blunting cravings through opioid receptor partial agonism, and providing a stable platform for recovery. The evidence base for MAT is massive and robust. Anyone suggesting patients should choose ketamine instead of MAT is giving dangerous advice.

Ketamine is not a "cure" for addiction. No single treatment is. Opioid use disorder is a chronic brain disease with social, psychological, and neurobiological components. Treatment requires a comprehensive approach.

Ketamine carries its own addiction potential. Ketamine can be habit-forming when used compulsively. Medical supervision, appropriate dosing intervals, and careful patient selection are essential. At-home ketamine for patients with active, uncontrolled OUD is generally not appropriate.

Who Might Be Appropriate Candidates

Based on current evidence, ketamine as an adjunct in OUD treatment is most appropriate for:

• Patients in stable recovery (on MAT or abstinent) with significant comorbid depression or PTSD that is driving relapse risk
• Patients with chronic pain that has been managed with opioids, where ketamine's analgesic effects could support opioid dose reduction
• Patients in residential or intensive outpatient programs where ketamine can be administered under close supervision
• Patients in supervised detoxification settings where the craving-reduction evidence is most applicable

Patients with active, unsupervised heavy opioid use are generally not appropriate for at-home ketamine. This requires an honest conversation with your physician about where you are in your recovery journey.

The Mechanism: Why Ketamine Might Help with Addiction

The neurological story is compelling. Addiction, at its core, involves dysregulation of the glutamatergic system — the signaling pathways that govern learning, memory, and salience. Drugs of abuse, including opioids, profoundly alter glutamate signaling in the nucleus accumbens, prefrontal cortex, and hippocampus — creating the powerful cue-triggered memories and reward associations that drive craving.

Ketamine's NMDA antagonism directly modulates these glutamatergic circuits. It may disrupt the reconsolidation of cue-drug memories — essentially weakening the neurological pull of people, places, and situations associated with opioid use. It also restores prefrontal cortical function, which supports better inhibitory control over impulsive craving responses.

Think of it as addressing the neurological wiring of addiction, not just managing withdrawal symptoms.

The Depression Connection Is Central

If we're being precise about why ketamine might be most valuable in OUD: it's the depression.

Depression drives relapse more than almost any other factor. Patients who complete detox and MAT successfully but don't address their underlying depression are at high risk of relapse — because the depression that opioids were managing doesn't go away just because the opioids do.

Ketamine's ability to produce rapid, powerful antidepressant effects — in patients for whom SSRIs often haven't worked well — directly addresses this core relapse driver. See understanding treatment-resistant depression and ketamine after antidepressant failure for more on this mechanism.

Moving Forward: A Conversation, Not a Protocol

If you or someone you love is in recovery from opioid use disorder and dealing with persistent depression, PTSD, or craving pressure, ketamine is worth a serious, honest conversation with a physician.

That conversation needs to include:

• Current MAT status and stability
• History of opioid use and current sobriety
• Psychiatric history, including depression and trauma
• Pain conditions and current analgesic regimen
• Honest assessment of addiction risk factors

We approach every OUD-adjacent conversation with care, respect, and non-judgment. Recovery is not linear, and the goal is always the same: helping people live better, more stable, more connected lives.

Take our eligibility quiz to begin that conversation with our physician team. Or browse our full resource library for more information. We review every case personally and will give you an honest, individualized assessment.